ATE300292T1 - Thyroxin-analoge mit keiner signifikanten hormonellen aktivität zur behandlung von bösartigen tumoren - Google Patents

Thyroxin-analoge mit keiner signifikanten hormonellen aktivität zur behandlung von bösartigen tumoren

Info

Publication number
ATE300292T1
ATE300292T1 AT97927813T AT97927813T ATE300292T1 AT E300292 T1 ATE300292 T1 AT E300292T1 AT 97927813 T AT97927813 T AT 97927813T AT 97927813 T AT97927813 T AT 97927813T AT E300292 T1 ATE300292 T1 AT E300292T1
Authority
AT
Austria
Prior art keywords
malignant tumors
thyroxine
hormonal activity
treatment
thyroxine analogues
Prior art date
Application number
AT97927813T
Other languages
English (en)
Inventor
Ernest Kun
Jerome Mendeleyev
Original Assignee
Octamer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/655,267 external-priority patent/US5736576A/en
Application filed by Octamer Inc filed Critical Octamer Inc
Application granted granted Critical
Publication of ATE300292T1 publication Critical patent/ATE300292T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
    • C07C69/92—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with etherified hydroxyl groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT97927813T 1996-06-04 1997-05-30 Thyroxin-analoge mit keiner signifikanten hormonellen aktivität zur behandlung von bösartigen tumoren ATE300292T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/655,267 US5736576A (en) 1996-06-04 1996-06-04 Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
US08/833,272 US6017958A (en) 1996-06-04 1997-04-03 Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
PCT/US1997/009086 WO1997046228A1 (en) 1996-06-04 1997-05-30 Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity

Publications (1)

Publication Number Publication Date
ATE300292T1 true ATE300292T1 (de) 2005-08-15

Family

ID=27096941

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97927813T ATE300292T1 (de) 1996-06-04 1997-05-30 Thyroxin-analoge mit keiner signifikanten hormonellen aktivität zur behandlung von bösartigen tumoren

Country Status (15)

Country Link
US (1) US6017958A (de)
EP (1) EP0954299B1 (de)
JP (1) JP4188416B2 (de)
CN (1) CN1154486C (de)
AT (1) ATE300292T1 (de)
AU (1) AU730261B2 (de)
BR (1) BR9710686A (de)
CA (1) CA2257235C (de)
DE (1) DE69733834T2 (de)
DK (1) DK0954299T3 (de)
ES (1) ES2246514T3 (de)
IL (1) IL127384A0 (de)
NZ (1) NZ333356A (de)
PT (1) PT954299E (de)
WO (1) WO1997046228A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922775A (en) * 1997-10-23 1999-07-13 Octamer, Inc. Method of treating malignant tumors with ketone thyroxine analogues having no significant hormonal activity
AU3109199A (en) * 1998-03-25 1999-10-18 Large Scale Biology Corporation Benzoates derivatives for inhibiting angiogenesis
US6433012B1 (en) * 1998-03-25 2002-08-13 Large Scale Biology Corp. Method for inhibiting inflammatory disease
US6740680B1 (en) * 1999-04-26 2004-05-25 Becton Pharma, Inc. Pharmaceutical compositions to tetrac and methods of use thereof
US6638977B1 (en) 1999-11-19 2003-10-28 Corvas International, Inc. Plasminogen activator inhibitor antagonists
WO2001036351A2 (en) 1999-11-19 2001-05-25 Corvas International, Inc. Plasminogen activator inhibitor antagonists related applications
US20050159490A1 (en) * 2001-01-31 2005-07-21 Eugene Morkin Method to treat chronic heart failure and/or elevated cholesterol levels
US7504435B2 (en) * 2001-01-31 2009-03-17 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method for stimulating weight loss and/or for lowering triglycerides in patients
AUPR500201A0 (en) 2001-05-14 2001-06-07 Commonwealth Scientific And Industrial Research Organisation Recovery of minerals by flotation
WO2003104181A2 (en) 2002-06-06 2003-12-18 Canbas Co. Ltd. Compounds that abrogate dna-damage-induced cell cycle g2 checkpoint and/or augment the anti-cancer activity of dna-damaging treatments
JP2007501608A (ja) * 2003-08-08 2007-02-01 株式会社 キャンバス 抗癌治療の効力を推定するための感受性試験
US20050249667A1 (en) * 2004-03-24 2005-11-10 Tuszynski Jack A Process for treating a biological organism
CA2615374A1 (en) * 2005-07-18 2007-01-25 Ernest Kun Kun Treatment of cancer
EP1953148B1 (de) 2005-10-28 2012-02-29 Takeda Pharmaceutical Company Limited Heterocyclische amidverbindung und anwendung davon
WO2008147418A1 (en) * 2006-06-12 2008-12-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20100279327A1 (en) * 2006-06-12 2010-11-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20080262062A1 (en) * 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
JP2010502730A (ja) * 2006-09-05 2010-01-28 バイパー サイエンシズ，インコーポレイティド 癌の治療法
US7538252B2 (en) * 2006-09-05 2009-05-26 Bipar Sciences, Inc. Drug design for tubulin inhibitors, compositions, and methods of treatment thereof
CA2662337A1 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof
AU2007292302A1 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Methods for designing PARP inhibitors and uses thereof
US8133859B2 (en) * 2006-09-27 2012-03-13 The United States Of America As Represented By The Department Of Health And Human Services SCGB3A2 as a growth factor and anti-apoptotic agent
WO2009051815A1 (en) * 2007-10-19 2009-04-23 Bipar Sciences, Inc. Methods and compositions for the treatment of cancer using benzopyrone-type parp inhibitors
KR20100102607A (ko) * 2007-11-12 2010-09-24 바이파 사이언스 인코포레이티드 Ｐａｒｐ 억제제를 단독으로 사용하거나 항종양제와 병용하여 자궁암 및 난소암을 치료하는 방법
CN103169973A (zh) * 2007-11-12 2013-06-26 彼帕科学公司 使用4-碘-3-硝基苯甲酰胺化合物与抗肿瘤剂组合治疗乳腺癌
CA2708157A1 (en) * 2007-12-07 2009-06-11 Bipar Sciences, Inc. Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors
CA2713156A1 (en) * 2008-02-04 2009-08-13 Bipar Sciences, Inc. Methods of diagnosing and treating parp-mediated diseases
US9655984B2 (en) 2010-04-28 2017-05-23 Osnat Ashur-Fabian Methods, compositions and kits for providing a therapeutic treatment
HRP20171784T1 (hr) * 2012-08-20 2017-12-29 Merck Patent Gmbh Kruti farmaceutski pripravak koji sadrži levotiroksin
US10874641B2 (en) 2016-07-28 2020-12-29 Mitobridge, Inc. Methods of treating acute kidney injury
AU2017355402A1 (en) 2016-11-02 2019-05-30 Health Research, Inc. Combination treatment with antibody-drug conjugates and PARP inhibitors
US11433074B2 (en) 2017-06-22 2022-09-06 Triact Therapeutics, Inc. Methods of treating glioblastoma
US11628144B2 (en) 2017-09-29 2023-04-18 Triact Therapeutics, Inc. Iniparib formulations and uses thereof
US11874276B2 (en) 2018-04-05 2024-01-16 Dana-Farber Cancer Institute, Inc. STING levels as a biomarker for cancer immunotherapy
US20220305048A1 (en) 2019-08-26 2022-09-29 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB643089A (en) * 1947-10-23 1950-09-15 Glaxo Lab Ltd Improvements in or relating to the preparation of 2:6-dihalogeno diphenyl ethers
GB642159A (en) * 1947-10-23 1950-08-30 Glaxo Lab Ltd Improvements in or relating to the preparation of diphenyl ethers
US4724234A (en) * 1982-09-17 1988-02-09 Therapeutical Systems Corp. Method for producing oncolysis
US4816255A (en) * 1985-07-31 1989-03-28 Ghent William R Treatment of iodine deficiency breast syndrome
WO1993002444A1 (fr) * 1991-07-24 1993-02-04 Vladislav Vladimirovich Volkov Dispositif tendeur pour instrument de musique a cordes a clavier
AU4090093A (en) * 1992-05-29 1993-12-30 Yamanouchi Pharmaceutical Co., Ltd. Medicine containing benzoic acid derivative and novel benzoic acid derivative
US5736576A (en) * 1996-06-04 1998-04-07 Octamer, Inc. Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
US5883294A (en) * 1997-06-18 1999-03-16 The Regeants Of The University Of California Selective thyroid hormone analogs
US5922775A (en) * 1997-10-23 1999-07-13 Octamer, Inc. Method of treating malignant tumors with ketone thyroxine analogues having no significant hormonal activity

Also Published As

Publication number Publication date
ES2246514T3 (es) 2006-02-16
CN1226826A (zh) 1999-08-25
JP4188416B2 (ja) 2008-11-26
PT954299E (pt) 2005-11-30
AU730261B2 (en) 2001-03-01
CA2257235C (en) 2007-01-30
US6017958A (en) 2000-01-25
EP0954299A4 (de) 2000-09-06
DK0954299T3 (da) 2005-10-31
AU3218297A (en) 1998-01-05
NZ333356A (en) 2000-06-23
CA2257235A1 (en) 1997-12-11
EP0954299A1 (de) 1999-11-10
WO1997046228A1 (en) 1997-12-11
EP0954299B1 (de) 2005-07-27
JP2001501590A (ja) 2001-02-06
BR9710686A (pt) 2000-01-11
DE69733834T2 (de) 2006-06-01
CN1154486C (zh) 2004-06-23
DE69733834D1 (de) 2005-09-01
IL127384A0 (en) 1999-10-28

Similar Documents

Publication Publication Date Title
ATE300292T1 (de) Thyroxin-analoge mit keiner signifikanten hormonellen aktivität zur behandlung von bösartigen tumoren
ATE222489T1 (de) Thyroxin-analoga ohne bedeutende hormonale wirkung zur behandlung von bösartigen tumoren
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
DE69631478D1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
DE69826695D1 (de) Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
DE69634900D1 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
ATE347366T1 (de) Verwendung von activem vitamin d analoga zur behandlung von prostataerkrangkungen
DE69736745D1 (de) Verfahren zur behandlung von prostaterkrankungen unter verwendung von vitamin-d-formulierungen mit verzögerter und/oder verlängerter wirkstofffreigabe
DE69127175D1 (de) Antisens-Oligonukleotide zur Behandlung von Krebs
ATE76294T1 (de) Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit.
ATE331534T1 (de) Anwendung von zielgerichtetem radium 223 für palliative und therapeutische behandlung von knochenkrebs
ATE282425T1 (de) Verfahren zur behandlung von endothelialen verletzungen
DE3789082D1 (de) Expression eines tumorspezifischen Antigens eines rekombinanten Virusvektors sowie dessen Anwendung zur versorgenden oder heilenden Behandlung des entsprechenden Tumors.
ATE311853T1 (de) Verwendung von krillenzymen zur behandlung von zahnbelag
ATE222769T1 (de) Verabreichung von gm-csf zur behandlung der gehirntumoren und verhütung deren wiederauftretens
DE69724682D1 (de) Verwendung von Gonadotropin releasing Hormon Analogen oder änlichen Verbindungen zur Herstellung von pharmazeutischen Zubereitungen als Zusatz für invasiver Behandlung von Karzinomen
NO994330D0 (no) Metode for behandling av en tumor
NO932101L (no) Polypeptidmateriale som er anvendelig ved terapeutisk behandling av mennesker
ES2179204T3 (es) Hidrazinas 2-aminocarbonil-1,2-bis(metilsulfonil)-1-sustituidas antitumorales.
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
DE59902666D1 (de) Edelfosin zur behandlung von hirntumoren
ATE181240T1 (de) Verwendung von somatostatinanalogen zur behandlung von melanomen
DE69218200D1 (de) Behandlung von leberkrebs
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
DE69732851D1 (de) Verwendung von dextrinsulfat zur behandlung von sehr vasculären tumoren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0954299

Country of ref document: EP